JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Pulmonary microbiome and metabolome signatures associate with chemotherapy response in lung cancer patients

  • 0Department of Respiratory and Critical Care Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Frontiers in Microbiology +

|

June 30, 2025

|

June 30, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Lung cancer patients

Area Of Science

  • Pulmonary medicine
  • Oncology
  • Microbiome research
  • Metabolomics

Background

  • Lung cancer chemotherapy response varies greatly.
  • Pulmonary microbiota and metabolome roles are unclear.
  • Investigating these factors may improve treatment.

Purpose Of The Study

  • To explore microbial and metabolic differences in lung cancer patients.
  • To identify biomarkers predicting chemotherapy response.

Main Methods

  • Collected bronchoalveolar lavage fluid (BALF) from 25 lung cancer patients.
  • Performed 16S rDNA sequencing and untargeted metabolomics (LC-MS).
  • Analyzed serum bile acids.

Main Results

  • Identified 92 altered metabolites in BALF; trans-urocanate and phenylalanylphenylalanine were key.
  • Enriched pathways include ABC transporters and bile acid biosynthesis.
  • Found differential bacterial genera (Caulobacter, Acinetobacter) and elevated serum bile acids in sensitive patients.

Conclusions

  • Distinct microbial and metabolic signatures correlate with chemotherapy response.
  • Potential biomarkers for personalized lung cancer therapy identified.

Keywords: